Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Pharma Oncology, Inc.

Sumitomo Pharma Co., Ltd.

Sumitomo Dainippon Pharma Oncology, Inc.

Astrazeneca Aktiebolag

Sumitomo Pharma America, Inc.

Hirotaka Kurebayashi

Hiroaki Tanaka

Seiji Hori

Futoshi Hasegawa

Daisuke Urabe

Adam Siddiqui-Jain

Shuji Masumoto

Paul Flynn

Takahiko Hashizuka

Yuka Arikawa

Yuji Fujiwara

A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.

CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R, R, Rm, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.

Carboxylic acid compounds

The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer. 

Growing community of inventors

Osaka, Japan

Hirotaka Kurebayashi